ALX ONCOLOGY HLDGS INC's ticker is ALXO and the CUSIP is 00166B105. A total of 109 filers reported holding ALX ONCOLOGY HLDGS INC in Q4 2021. The put-call ratio across all filers is 3.95 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $919,315 | -36.5% | 191,524 | -0.6% | 0.00% | – |
| Q2 2023 | $1,447,192 | +61.3% | 192,702 | -2.9% | 0.00% | – |
| Q1 2023 | $897,477 | -60.8% | 198,557 | -2.2% | 0.00% | – |
| Q4 2022 | $2,287,033 | -17.5% | 202,931 | -30.0% | 0.00% | -100.0% |
| Q3 2022 | $2,772,000 | +71.3% | 289,767 | +44.9% | 0.00% | – |
| Q2 2022 | $1,618,000 | -44.9% | 199,986 | +15.1% | 0.00% | -100.0% |
| Q1 2022 | $2,935,000 | -21.4% | 173,694 | -0.1% | 0.00% | 0.0% |
| Q4 2021 | $3,735,000 | -71.0% | 173,805 | -0.5% | 0.00% | -50.0% |
| Q3 2021 | $12,901,000 | +37.9% | 174,664 | +2.1% | 0.00% | 0.0% |
| Q2 2021 | $9,353,000 | -28.0% | 171,040 | -2.8% | 0.00% | 0.0% |
| Q1 2021 | $12,983,000 | +25.5% | 176,050 | +46.7% | 0.00% | 0.0% |
| Q4 2020 | $10,348,000 | +136.8% | 120,047 | +3.7% | 0.00% | +100.0% |
| Q3 2020 | $4,370,000 | – | 115,816 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| venBio Partners LLC | 9,699,925 | $715,272,000 | 67.97% |
| Logos Global Management LP | 3,156,981 | $232,796,000 | 22.72% |
| Vivo Capital, LLC | 4,220,048 | $311,186,000 | 10.94% |
| Foresite Capital Management IV, LLC | 785,945 | $57,956,000 | 6.94% |
| Foresite Capital Management V, LLC | 320,000 | $23,597,000 | 6.94% |
| Board of Trustees of The Leland Stanford Junior University | 518,822 | $38,258,000 | 3.38% |
| Cormorant Asset Management, LP | 881,770 | $65,022,000 | 1.45% |
| Redmile Group, LLC | 978,600 | $72,162,000 | 1.02% |
| SPHERA FUNDS MANAGEMENT LTD. | 130,351 | $9,612,000 | 0.74% |
| Artal Group S.A. | 525,000 | $38,714,000 | 0.68% |